About Prestige biopharma pte ltd
Prestige Biopharma Pte Ltd: Revolutionizing the Biopharmaceutical Industry
Prestige Biopharma Pte Ltd is a Singapore-based biopharmaceutical company that specializes in the development and manufacturing of biosimilars. The company was founded in 2008 with a mission to provide affordable and high-quality biologic drugs to patients worldwide.
With its state-of-the-art facilities and cutting-edge technology, Prestige Biopharma has become a leading player in the global biosimilar market. The company's portfolio includes several biosimilars for cancer treatment, including PAUF, HD201, HD204, Tozumab, VespoDA, and Pafuramab.
PAUF is Prestige Biopharma's flagship product. It is a monoclonal antibody that targets pancreatic cancer cells. PAUF has shown promising results in preclinical studies and is currently undergoing clinical trials. If successful, it could become an important treatment option for patients with pancreatic cancer.
HD201 and HD204 are biosimilars of Herceptin (trastuzumab), a drug used to treat breast cancer. Tozumab is a biosimilar of Avastin (bevacizumab), which is used to treat various types of cancer. VespoDA is a biosimilar of Remicade (infliximab), which is used to treat autoimmune diseases such as rheumatoid arthritis.
Pafuramab is another promising product from Prestige Biopharma's pipeline. It targets ovarian cancer cells and has shown excellent results in preclinical studies.
In addition to its biosimilar portfolio, Prestige Biopharma also offers contract development and manufacturing services for other companies in the biotech industry. Its state-of-the-art facilities are equipped with advanced technologies such as single-use bioreactors and continuous chromatography systems.
Prestige Biopharma's commitment to quality and innovation has earned it several accolades in the biopharmaceutical industry. In 2019, the company was awarded the Frost & Sullivan Asia-Pacific Biologics Manufacturer of the Year award.
Prestige Biopharma's biosimilars are approved for use in several countries, including Korea, Japan, and Europe. The company is also seeking approval from regulatory agencies in other regions such as the United States.
In conclusion, Prestige Biopharma Pte Ltd is a leading player in the global biosimilar market. Its commitment to quality and innovation has made it a trusted partner for companies in the biotech industry. With its promising pipeline of biosimilars and contract development services, Prestige Biopharma is poised to revolutionize the biopharmaceutical industry.